Newsbenzinga
Bristol Myers Squibb Moves Closer to New Multiple Myeloma Treatment
· Published
Article summary
FDA accepts Bristol Myers Squibb's mezigdomide NDA for relapsed multiple myeloma, with a PDUFA decision due May 13, 2027.
An excerpt from the original article.
Comments —
Loading comments…